

1FW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0701.187C

In Re Application Of: **Currie et al.**


Serial No.
10/633,086

Filing Date
08/01/2003

Examiner
Unknown

Group Art Unit
1617

Title: **CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0701.187C

In Re Application: Currie et al.

Serial No.
10/633,086

Filing Date
08/01/2003

Examiner
Unknown

Group Art Unit
1617

**CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN
B2 ADRENERGIC AGONISTS**



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 08-1935 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I certify that this document and fee is being deposited on June 2, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Martha L. Boden, Esq.

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.


Signature

Dated: June 2, 2004

CC:

SUPPLEMENTAL INFORMATION DISCLOSURE	Docket No.: 0701.187C	Serial No.: 10/633,086
	Inventor(s): Currie et al.	Examiner:
	Filing Date: 08/01/2003	GAU:



UNITED STATES PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AC	3,056,727	10/02/62	Allais et al.	167	74	October 17, 1961
	AD	3,329,570	07/04/67	Allais et al.	167	65	December 18, 1964

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Int'l Class	Int'l Subclass	Translation	
							Yes	No
	BC	DE19541689	05/15/96	Germany			Abstract Only	
	BD	WO92/13873	08/20/92	PCT			X	
	BE	WO93/11773	06/24/93	PCT			X	
	BF	WO01/78742	10/25/01	PCT			X	
	BG	WO03/070745	08/28/03	PCT			X	
	BH	126929	04/06/72	England			X	

OTHER DOCUMENTS

(Including Author, Title, Date Pertinent Pages, Etc.)

	CE	XP008009269; Creticos et al., "Comparison of Triamcinolone Acetonide (TAA), Salmeterol Xinafate (SMT), TAA + SMT, and Placebo (PL) in Mild - Moderate Asthmatics," <i>European Respiratory Journal</i> , 12 (28), 1565 (1998).
	CF	XP001013661; McGavin et al., "Inhaled Budesonide/Formoterol Combination," <i>Drugs</i> 61, 71-78 (2001).

EXAMINER:	Date Considered
-----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.